Drug-induced liver injury (DILI) continues to be the leading cause of attrition during drug development in all phases of clinical trials as well as the number one cause of post-market drug withdrawal. CELLBLOKS® liver-on-a-chip models are the only platforms in the market that is industry compliant, hight-throughput and in-vivo relevant, containing precise spatial and structural arrangement of different cell types enabling cell-cell communication and in-vivo like metabolic function essential for predicting adverse drug effects. We can generate high quality and human-relevant data rapidly and in cost-effective manner.
CELLBLOKS® 2D layout Liver-on-a-Chip model
Human hepatocytes HepG2 cells*, Human endothelial HUVEC cells* & Fibroblast cell*
*other cell type options on request
Test Compound Concentrations
4 point dose response curve with top concentration based on 100x Cmax or solubility limit. 3 replicates per concentration.*
*Extend compound screening with more plates
150 μL of a solution to achieve 100x Cmax (200 x top concentration to maintain 0.5% DMSO) or equivalent amount in solid compound.